Tolerability of Utidelone Capsule in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to evaluate the safety and tolerability of Utidelone Capsule in
patients with advanced solid tumors and determine the maximum tolerated dose (MTD) and
dose-limiting toxicity (DLT). The secondary objectives are to evaluate the pharmacokinetic
profile of Utidelone Capsule in patients with advanced solid tumors, preliminarily assess the
anti-tumor activity of Utidelone Capsule in patients with advanced solid tumors via objective
radiologic tumor response using RECIST 1.1, and to recommend the dose and dosage regimen for
subsequent clinical trials.